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clinically acceptable, however the H&N FFF plans have lower 
pass rates. This can be related to the MLC modulation needed 
to compensate for the inhomogeneous beam profile using FFF 
for larger targets. Same trend is seen for the lung 
treatments, where there is a range of target sizes. 
 
 
Conclusions: Clinically acceptable FFF treatment plans can 
be created and delivered for normally fractionated 
treatments in all three anatomical sites. The reduced head 
scatter from removing the flattening filter produces reduced 
total body dose, which could be clinically relevant to the aim 
of reducing secondary cancers. 
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Purpose/Objective: Evaluation of the characteristics of the 
new EPID PV-aS1200 by Varian for its dosimetric usage with 
the GLAaS algorithm, where a dedicate configuration phase 
allows to convert the EPID reading into absorbed dose to 
water. 
Materials and Methods: The new PV-aS1200 imager has an 
active area of a 40x40cm2 (1190x1190 pixel), with a 
backscatter shielding included in the new cassette 
engineering. Its intrinsic characteristics were investigated on 
an Edge accelerator equipped with 6X, 6FFF, 10FFF beams. 
For the same energies, data were also compared to PV-
aS1000 acquisitions from a TrueBeam.  
A first level of investigations covered signal linearity with 
dose, response to primary and transmitted radiation, 
saturation relative to dose and dose rate, arm backscatter as 
a function of field size, ghosting. After that first detector 
assessment, the robustness of the GLAaS dose calibration 
process was evaluated in terms of absolute absorbed dose, 
relative output factors and profile parameters. 
Finally, GLAaS was validated for aS1200 as pre-treatment QA 
tool for RapidArc plans, covering different dose/fraction 
prescriptions. The mutual position of the detector and the 
linac head was measured in a cine mode during full rotations. 
Results: For all energies, aS1200 readings showed an optimal 
linearity relative to MU (R2=1.00), with a residual deviation 
less than 0.5% for more than 3MU. The detector response to 
primary and transmitted radiation was modelled and showed 
to be similar to the aS100 detector. The aS1200 confirmed to 
have no saturation for measurements at isocenter and the 
maximum dose rate (1400 and 2400 MU/min for 6 and 10FFF 
respectively). The arm backscatter variation with field size is 
now compensated with the new engineering. Consequently 
the dose calibration according to the GLAaS model was 
successfully implemented, allowing QA for all beams with no 
limitations of field size or dose rate.  
Comparison between measured dose map and TPS calculated 
dose in water was assessed through the Gamma Agreement 
Index GAI, for different DTA and ΔD criteria, resulting in GAI 
> 95% (2%, 2mm criteria).  
Conclusions: The new aS1200 detector improved the 
performance of the previous aS1000, with no more limitation 
in terms of field size and/or dose rate. The effective 
resolution of arm backscatter allows a more robust usage of 
the new detector. The usability for pre-treatment QA for 
RapidArc cases is confirmed in all conditions, from 
stereotactic to very large volumes, from common to very high 
dose rates. 
 
 
Poster: Physics track: Treatment planning calculation, 
optimisation  
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Purpose/Objective: By creating Pareto fronts for Helical 
TomoTherapy (HT) plans, the influence of field width (FW), 
modulation factor (MF) and pitch on the plan quality can be 
investigated and Pareto optimal combinations can be 
deduced. 
Materials and Methods: For every oropharyngeal cancer 
patient out of five, 90 TomoEdge plans were made (each with 
a unique combination of MF and pitch) [1-2]. The 
homogeneity index (HI), conformity index (CI), Dnear-max (D2) 
and Dnear-min (D98) of the PTVs were plotted in a Pareto front 
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as well as the mean dose or specific critical doses of 10 
organs at risk (OARs). 
Pareto fronts are well suited for plan comparison as a Pareto 
optimal solution is obtained when one objective cannot be 
improved without deteriorating another [3]. In this study 
Pareto fronts are created by varying one parameter (pitch or 
MF), while anchoring the others. 
Results: For small pitches (0.10-0.20), MF does only influence 
plan quality. For these conditions treatment time is 
invariable because gantry period already reached its minimal 
value of 12sec. Increasing the pitch (≥ 0.25) will in general 
reduce treatment time and for these larger pitches, lowering 
MF will additionally lower treatment time but also PTV 
coverage and OAR sparing will vary. 
The Pareto fronts in figure 1 cover a wide range of Pareto 
optimal combinations: from pitch 0.10 and MF 3.0 to pitch 
0.50 and MF 1.2. Despite the Pareto optimality of these 
points, not all of them result in clinical acceptable plans. The 
combination of a large pitch (0.50) and a low MF results in a 
fast treatment of 1m56 at the price of unacceptable doses to 
OARs. On the other site of the Pareto front, small pitches 
(0.10-0.20) introduce too much overlap between adjacent fan 
beams. Due to this excess of modulation possibilities and 
although OARs can be maximally spared, this will result in an 
unnecessary long treatment time of 8m58. 
MF and pitch both have an impact on plan quality/treatment 
time and consequently it is a planner responsibility to choose 
the patient specific, preferable combination. 
Conclusions: This Pareto front study shows that with 
TomoEdge for a FW of 5cm clinical acceptable Pareto optimal 
combinations exist if pitch and MF are chosen in a range of 
[0.30-0.45] and [2.0-3.0] respectively. These values generate 
plans with on one hand a minimised dose to the OARs and on 
the other hand minimised HI and CI for the PTVs. The 
corresponding treatment time varies from 2m36 to 3m50s. 
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Purpose/Objective: Dose-volume (Dvh hereafter) plan 
evaluation and inverse optimization is an accepted standard 
of care in external beam radiotherapy. Recently, inverse 
optimization based on energy minimization (Energy 
hereafter) was suggested as a possible alternative. The 
purpose of this work is to apply Dvh and Energy based inverse 
optimization in NSCLC, and to compare the performance of 
each approach. 
Materials and Methods: Fourteen lung patient plans were 
retrospectively optimized for IMRT. For each subject, the 
target had an estimated range of motion of less than 0.5 cm, 
and therefore no motion management was considered. The 
optimization was performed with Dvh and Energy based 
objective functions. Those different objectives were used 
only for the organs at risk (OARs). For the planning target 
volumes (PTVs) minimum, maximum, and uniform dose 
objectives were used with either optimization. In each 
optimization the CT dataset corresponding to mid-ventilation 
was used. With either optimization nine equally spaced 
beams were used. Step-and-shoot IMRT with total of 72 
segments was used in each plan. The minimum allowed 
segment area and minimum monitor units (MUs) per segment 
were set the same for both optimization approaches. Dvh and 
